Introduction
============

Although most pancreatic cancers are diagnosed at advanced stage, around 50% of pancreatic cancer patients present with localized disease without evident distant metastasis. Locally advanced pancreatic cancers (LAPC) include a heterogenous spectrum of disease from borderline resectable to unresectable tumors \[[@b1-crt-2017-105]\]. Chemoradiotherapy was once the standard of care for LAPC \[[@b2-crt-2017-105]\]. With gemcitabine becoming the preferred treatment strategy for advanced pancreatic cancer \[[@b3-crt-2017-105]\], clinical trials comparing chemoradiotherapy with gemcitabine alone in LAPC patients showed mixed results \[[@b4-crt-2017-105],[@b5-crt-2017-105]\]. Meta-analysis revealed similar clinical outcomes using up-front chemoradiotherapy followed by chemotherapy versus chemotherapy alone in LAPC \[[@b6-crt-2017-105]\].

The development of induction chemotherapy (ICT) followed sequentially by consolidation chemoradiotherapy (CCRT) was based on the rationale of sparing patients with rapidly progressive disease from radical local radiotherapy. Some retrospective studies suggested that this approach could improve survival of LAPC \[[@b7-crt-2017-105],[@b8-crt-2017-105]\]. The only prospective randomized trial evaluating CCRT in addition to chemotherapy revealed an increase in progression-free survival (PFS), resulting in longer period without treatment (6.1 months vs. 3.7 months, p=0.02), and a decrease in local progression (32% vs. 46%, p=0.03); while no survival benefit was observed \[[@b9-crt-2017-105]\]. However, the 68% minor to major radiation protocol violation in LAP07 study might underestimate the effect of chemoradiotherapy \[[@b10-crt-2017-105]\]. Another possibility contributing to the lack of overall survival (OS) benefit of CCRT might be the dominant effect of metastatic disease due to ineffective systemic chemotherapy.

Many prospective studies evaluating modern chemotherapy alone or ICT followed by CCRT in LAPC have been published, but the sample sizes of most studies were too small to draw definite conclusions. To evaluate the efficacy of CCRT after ICT and provide further information for the design of clinical trials, we conducted a systematic review and meta-analysis of prospective clinical trials that investigated the efficacy of chemotherapy alone or ICT followed by CCRT in treating LAPC.

Materials and Methods
=====================

A protocol was developed to collect data from prospective clinical trials for LAPC patients. The details were defined in a prospectively registered protocol available online (PROSPERO identifier CRD42016047182). The reporting of the current study adheres to the criteria included in the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) \[[@b11-crt-2017-105]\].

Prospective clinical trials published in English were identified by searching PubMed, Embase, MEDLINE, Web of Science from the date of inception of each database to January 2016. The search included the following terms: "pancreatic cancer," "pancreatic carcinoma," "pancreatic adenocarcinoma,\" and "locally advanced," "unresectable," "non-metastatic." Additional clinical trials were identified by reviewing the previous meta-analyses.

1. Eligibility criteria
-----------------------

To be included in the meta-analysis, the study had to meet all the following criteria: (1) patients were locally advanced pancreatic ductal adenocarcinoma.; (2) prospective phase II or randomized trials; (3) treatment with chemotherapy alone or ICT followed by CCRT; (4) reported outcomes of interests, including 1-year survival rate and median OS ([S1 Table](#SD1-crt-2017-105){ref-type="supplementary-material"}). When the eligibility criteria were met, the full article was then retrieved for further assessment. The discrepancies between two investigators were resolved by consensus after discussion.

2. Data extraction and study endpoints
--------------------------------------

Data were extracted independently by two investigators (H.-J.C. and J.S.C.) using a predefined data extraction sheet. The primary end-point was 1-year survival rate. Secondary end-points were PFS, median OS, toxicity, and resection rate.

3. Statistical analysis
-----------------------

The current meta-analysis on 1-year survival rate was performed with R function metaprop in R package meta \[[@b12-crt-2017-105]\] using R statistical software ver. 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). Both the fixed-effects model and the random-effects model were used to perform meta-analysis. We applied Freeman-Tukey double arcsine transformation to 1-year survival rate to calculate the pooled estimates of proportions and their corresponding 95% confidence intervals \[[@b13-crt-2017-105]\]. Heterogeneity between studies was evaluated by I2 statistic with I2= 0%-24.9%, 25%-49.9%, and ≥ 50% representing low, moderate, and high heterogeneity, respectively \[[@b14-crt-2017-105]\]. The Cochran statistic was calculated to assess the significance level of I^2^ statistic \[[@b15-crt-2017-105]\]. A p-value of \< 0.05 indicated a significant heterogeneity between studies, and results generated by the random-effects models were reported. Results from the fixed-effects models were included when the homogeneity assumption was not violated (p \> 0.05). Forest plot was used to display the probabilities of individual studies. The analysis was first performed to assess the overall difference in 1-year survival rate between the two treatment groups. Additional analyses were performed by study year, randomization, resectability status, number of chemotherapy agents, ICT duration, maintenance chemotherapy, radiotherapy dosage, and radiosensitizer. Statistical significance was determined by examining the 95% confidence intervals (CIs). The comparison between chemotherapy versus ICT+CCRT was deemed statistically significant when the 95% CIs did not overlap. Funnel plot and Egger's regression asymmetry test were used to evaluate publication bias \[[@b16-crt-2017-105],[@b17-crt-2017-105]\].

Results
=======

[Fig. 1](#f1-crt-2017-105){ref-type="fig"} presents the flow chart depicting the study selection process. After screening the titles or abstracts of 2,659 studies identified using key words described in "Materials and Methods" ([S2 Table](#SD2-crt-2017-105){ref-type="supplementary-material"}), 192 studies were selected for full-text assessment, of which 106 studies were excluded due to retrospective analysis or studies enrolling metastatic/resectable patients, etc. ([S3 Table](#SD3-crt-2017-105){ref-type="supplementary-material"}). Another 18 studies were added after reviewing other meta-analyses of LAPC treatment. Of the 110 studies with 134 study arms, 85 arms were excluded due to studies using radiotherapy alone or upfront chemoradiotherapy ([S4 Table](#SD4-crt-2017-105){ref-type="supplementary-material"}). The 41 studies in the final meta-analysis included 12 randomized studies and 29 phase II studies ([S5 Table](#SD5-crt-2017-105){ref-type="supplementary-material"}). The quality of each trial was evaluated ([S6](#SD6-crt-2017-105){ref-type="supplementary-material"}-[S9 Tables](#SD9-crt-2017-105){ref-type="supplementary-material"}). Of the 49 study arms, 24 arms were chemotherapy alone ([Table 1](#t1-crt-2017-105){ref-type="table"}) \[[@b18-crt-2017-105]-[@b35-crt-2017-105]\] and 25 arms were ICT followed by CCRT ([Table 2](#t2-crt-2017-105){ref-type="table"}) \[[@b35-crt-2017-105]-[@b58-crt-2017-105]\].

A total of 1,018 patients received ICT+CCRT, and 954 patients received chemotherapy alone. Twelve (50%) and six (24%) study arms of chemotherapy alone and ICT+CCRT, respectively, administered single chemotherapy agent. Twelve and eight studies used 5-fluorouracil and gemcitabine, respectively, as radiosensitizer. Two studies using stereotactic body radiotherapy were without concomitant chemotherapy.

The meta-analysis showed that 1-year survival rate was not significantly different between chemotherapy alone (52%; 95% CI, 45 to 60) and ICT+CCRT (58%; 95% CI, 53 to 62) ([Fig. 2](#f2-crt-2017-105){ref-type="fig"}). Funnel plots disclosed significant publication bias of both groups of studies ([S10 Fig.](#SD10-crt-2017-105){ref-type="supplementary-material"}). Studies using ICT+CCRT had a significantly better 1-year survival rate than chemotherapy alone when the duration of ICT was 3 months or more (65%; 95% CI, 60 to 70 vs. 52%; 95% CI, 45 to 60) ([Table 3](#t3-crt-2017-105){ref-type="table"}). In randomized trials, a significantly better survival rate of the four ICT+CCRT studies was noted compared to that of the thirteen chemotherapy alone studies (67%; 95% CI, 60 to 73 vs. 47%; 95% CI, 38 to 56) ([Table 3](#t3-crt-2017-105){ref-type="table"}). Similar observations were noted in meta-analysis of median OS or median PFS as end points with less statistical significance ([S11 Table](#SD11-crt-2017-105){ref-type="supplementary-material"}). For both groups, smaller studies showed bias toward poorer survival. Of the 14 and 13 studies in chemotherapy alone and ICT+CCRT groups, respectively, published after year 2010, there was a trend of survival benefit in ICT+CCRT over chemotherapy alone groups (64%; 95% CI, 60 to 68 vs. 55%; 95% CI, 47 to 61).

Combination chemotherapy as induction therapy did not potentiate the benefit of consolidation CCRT compared to those using single agent (58%; 95% CI, 52 to 64 vs. 58%; 95% CI, 45 to 70) ([Table 3](#t3-crt-2017-105){ref-type="table"}). Maintenance chemotherapy after ICT+CCRT did not significantly affect the 1-year survival rate of LAPC compared to those with chemotherapy alone (59%; 95% CI, 52 to 65 vs. 52%; 95% CI, 45 to 60). However, in the 10 ICT+CCRT study arms using maintenance chemotherapy published after 2010, there appeared to be survival benefit compared to those 15 study arms using chemotherapy alone (66%; 95% CI, 62 to 70 vs. 55%; 95% CI, 47 to 61). The benefit of additional CCRT was not correlated with radiation dosage and the regimen of radiation sensitizer. However, a trend of survival benefit regarding ICT+CCRT over chemotherapy alone was found for using fluorouracil as radiosensitizer especially in studies published after 2010 (66%; 95% CI, 62 to 71 vs. 55%; 95% CI, 47 to 61).

Nine studies enrolling various proportion of patients with borderline disease had a trend of better survival. The survival benefit of ICT+CCRT over chemotherapy was not observed in studies enrolling unresectable disease alone or both borderline and unresectable pancreatic cancer ([Table 3](#t3-crt-2017-105){ref-type="table"}). Twenty studies reported resection after chemotherapy with or without chemoradiation. There was no significant correlation between resection and the use of CCRT (ICT+CCRT, 13%; 95% CI, 9 to 18 vs. chemotherapy alone, 23%; 95% CI, 11 to 34).

Seven of the 24 ICT+CCRT studies (29.2%) and nine of the 22 chemotherapy alone studies (40.9%) reported grade 3/4 toxicity rate of more than 30%. The development of hematologic (19%; 95% CI, 14 to 24 vs. 23%; 95% CI, 16 to 30) and non-hematologic toxicity (19%; 95% CI, 14 to 24 vs. 15%; 95% CI, 11 to 20) was not significantly different between ICT+ CCRT and chemotherapy alone.

Discussion
==========

The latest meta-analysis of randomized trials demonstrated no survival benefit of upfront chemoradiotherapy followed by chemotherapy versus chemotherapy alone \[[@b6-crt-2017-105]\]. Recent prospective clinical trials evaluating the role of CCRT after ICT in LAPC patients still revealed no survival benefit over chemotherapy alone \[[@b9-crt-2017-105]\]. Investigators suggested the incorporation of more active combination chemotherapy as induction therapy and modern radiotherapy techniques into the design of future clinical trials. To address the issue and provide further information, we conducted this systemic review and meta-analysis.

We found that there was no survival benefit of CCRT after ICT for LAPC from meta-analysis of 41 selected prospective clinical trials. The lack of survival benefit of CCRT in addition to chemotherapy was probably attributed to reasons including short duration of ICT, non-effective ICT regimen, non-optimal radiosensitizer, no maintenance chemotherapy in most clinical trials.

Subgroup analysis showed significant survival benefit of ICT+CCRT over chemotherapy alone when the duration of ICT lasted for at least three months. Consistent with our observation, a retrospective study from Johns Hopkins Hospital also demonstrated a significantly decreased cumulative incidence of progression (p=0.008) and a trend toward better OS (19.4 months vs. 15.7 months, p=0.10) in patients who received \> 2 cycles of chemotherapy before CCRT in LAPC \[[@b59-crt-2017-105]\].

The role of maintenance chemotherapy following ICT+ CCRT of LAPC is unknown. The CAIRO3 study evaluated the benefit of maintenance chemotherapy in metastatic colorectal cancer and found a significant improvement of PFS (11.7 months vs. 8.5 months, p \< 0.001) \[[@b60-crt-2017-105]\]. A retrospective study in pancreatic cancer also demonstrated the survival benefit of maintenance capecitabine after adjuvant treatment compared to adjuvant treatment alone with OS of 48.4 months vs 22.0 months (p \< 0.001) \[[@b61-crt-2017-105]\]. In this study, a trend of survival benefit of additional CCRT was noted by the 27 clinical trials published after year 2010 that provided maintenance chemotherapy.

Previous randomized trials revealed that the combination regimen of FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel improved the OS of advanced pancreatic cancer significantly compared to that treated with gemcitabine alone \[[@b62-crt-2017-105],[@b63-crt-2017-105]\]. In this analysis, we did not find the superiority of combination chemotherapy compared to single agent in chemotherapy alone studies, nor did we find the benefit of CCRT after ICT using combination regimen for LAPC patients. This result might be attributed to the lack of effective combination regimen in the 41 studies enrolled for meta-analysis. The ICT regimen most often used in the 25 study arms of our metaanalysis was gemcitabine with platinum analog which failed to improve survival over gemcitabine alone in several phase III trials in advanced pancreatic cancer \[[@b64-crt-2017-105],[@b65-crt-2017-105]\].

We found that ICT followed by 5-fluorouracil (5FU)-based CCRT showed a trend of better survival compared to chemotherapy alone. A recent randomized trial and a metaanalysis suggested a superiority for 5FU-based chemoradiotherapy over gemcitabine \[[@b66-crt-2017-105],[@b67-crt-2017-105]\]. Investigators demonstrated that TS-1 or capecitabine had similar efficacy compared to gemcitabine as radiosensitizers, although TS-1 and capecitabine were associated with fewer toxicities.

Our study has several limitations. The studies included in our meta-analysis were conducted at different times and resulted in heterogeneity in study subjects and treatment. The improvements in diagnostic imaging resulted in more accurate clinical staging of pancreatic cancer. The definition of LAPC had only been standardized recently. Some patients are now being reclassified as borderline resectable due to improvements in surgical techniques and perioperative care \[[@b68-crt-2017-105]\]. Besides, the various radiation dosages, target volumes, and techniques as well as different chemotherapy types and dosages administered might have affected the study results. Finally, potential publication bias exists for both the chemotherapy alone and ICT+CCRT groups, with smaller studies tended to show poorer survival. It is unclear how this publication bias might have affected our results; however, since the publication bias was in the same direction for both treatment groups, the overall impact should have been minimal.

Consensus guidelines of radiotherapy in LAPC have been developed to guide the desired doses and treatment volume \[[@b69-crt-2017-105]\]. Gemcitabine/nab-paclitaxel combination and FOLFIRINOX have been shown to improve disease control compared to gemcitabine alone in advanced pancreatic cancer. A recent randomized trial suggested a superiority of capecitabine as radiosensitizer over gemcitabine \[[@b66-crt-2017-105]\]. Investigator should consider the adoption of more active chemotherapy regimens as induction therapy and the incorporation of maintenance chemotherapy. The value of high-dose ablative stereotactic body radiotherapy should also be evaluated \[[@b70-crt-2017-105]\]. The development of biomarkers such as DPC4, Runx3 \[[@b1-crt-2017-105],[@b71-crt-2017-105]\], and radiation sensitivity analyses \[[@b72-crt-2017-105]\] to select patients at high risk of developing local destructive disease for CCRT treatment is warranted.

In summary, the role of CCRT after ICT in LAPC patients is evolving. Our meta-analysis revealed no survival benefit of CCRT in addition to chemotherapy for LAPC patients. However, significant survival benefit of ICT+CCRT over chemotherapy alone was noted when ICT lasted for at least 3 months. A trend of clinical benefit using 5FU-based CCRT, and maintenance chemotherapy were also noted for LAPC.
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###### 

Baseline characteristics of 24 cohort groups of chemotherapy alone for meta-analysis

  Author                                                                                Year   Patients                                             BR/UR (%)                                                               Chemotherapy                                                                                          Tx duration (wk)                                      Median OS (mo)   Median PFS (mo)   1-Year survival rate (%)   Resection rate (%)
  ------------------------------------------------------------------------------------- ------ ---------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------- ----------------- -------------------------- --------------------
  Hazel et al. \[[@b18-crt-2017-105]\]^[a)](#tfn1-crt-2017-105){ref-type="table-fn"}^   1981   15                                                   0/100                                                                   5FU 500 mg/m^2^ weekly+CCNU 100 mg/m^2^ every 6 wk                                                    na                                                    7.8              na                na                         0
  Klaassen et al. \[[@b19-crt-2017-105]\]                                               1985   44                                                   0/100                                                                   5FU 600 mg/m^2^ weekly                                                                                na                                                    8.2              4.2               28                         0
  GITSG \[[@b20-crt-2017-105]\]                                                         1988   21                                                   0/100                                                                   5FU 600 mg/m^2^ D1, 8, 29, 36+streptozocin 1+MMC 10 mg/m^2^ every 8 wk                                na                                                    8                na                19                         0
  Todd et al. \[[@b21-crt-2017-105]\]                                                   1998   38                                                   0/100                                                                   5FU 200 mg/m^2^ once a day+LV 30 mg/m^2^ weekly+MMC 10 mg/m^2^ every 6 wk+Dip 75 mg/m^2^ once a day   na                                                    15.5             8                 70                         16
  Conroy et al. \[[@b22-crt-2017-105]\]                                                 2005   11                                                   0/100                                                                   FOLFIRINOX                                                                                            16                                                    15.7             7.6               na                         0
  Isacoff et al. \[[@b23-crt-2017-105]\]                                                2007   54                                                   0/100                                                                   5FU 200 mg/m^2^ once a day+LV 30 mg/m^2^ weekly+MMC 10 mg/m^2^ every 6 wk                             24+                                                   13.8             7.3               54                         11.1
  Chauffert et al. \[[@b24-crt-2017-105]\]                                              2008   60                                                   0/100                                                                   Gem 1,000 mg/m^2^ weekly                                                                              24                                                    13               6.2               52                         0
  Ishii et al. \[[@b25-crt-2017-105]\]                                                  2010   50                                                   0/100                                                                   Gem 1,000 mg/m^2^ weekly                                                                              na                                                    15               6                 64                         0
  Loehrer et al. \[[@b26-crt-2017-105]\]                                                2011   37                                                   0/100                                                                   Gem 1,000 mg/m^2^ weekly                                                                              15                                                    9.2              6.7               33                         0
  Sahora et al. \[[@b27-crt-2017-105]\]                                                 2011   25                                                   48/52                                                                   Gem 900 mg/m^2^+Doc 35 mg/m^2^ weekly, 3/4 wk                                                         24                                                    13.5             11.8              40                         32
  Sahora et al. \[[@b28-crt-2017-105]\]                                                 2011   33                                                   45/55                                                                   Gem 900 mg/m^2^+Oxalip 60 mg/m^2^ weekly                                                              6-9                                                   16               10                45.5                       39
  Lee et al. \[[@b29-crt-2017-105]\]                                                    2012   43                                                   100/?                                                                   Gem 1,250 weekly+Cape 950 mg/m^2^ bid 2 wk/3 wk                                                       9-27^[a)](#tfn1-crt-2017-105){ref-type="table-fn"}^   16.6             10                70                         33
  Nakai et al. \[[@b30-crt-2017-105]\]                                                  2012   13                                                   0/100                                                                   Gem 1,000 mg/m^2^ weekly                                                                              na                                                    11               8.1               na                         0
                                                                                        15     0/100                                                Gem 1,000 mg/m^2^ D1, 15+TS1 40 mg/m^2^ twice a day D1-14, every 4 wk   na                                                                                                    23.9                                                  12.6             na                0                          
  Ozaka et al. \[[@b31-crt-2017-105]\]                                                  2012   18                                                   0/100                                                                   Gem 1,000 mg/m^2^ D1, 8, 15 every 4 wk                                                                na                                                    8.7              na                38.9                       0
                                                                                        13     0/100                                                Gem 1,000 mg/m^2^ D1, 15+TS1 40 mg/m^2^ D1-14 every 4 wk                na                                                                                                    14.6                                                  na               64.3              0                          
  Heinemann et al. \[[@b32-crt-2017-105]\]                                              2013   31                                                   0/100                                                                   Gem 1,000 mg/m^2^ weekly                                                                              22                                                    9.9              8.2               33.9                       0
  2013                                                                                  31     0/100                                                Gem 1,000 mg/m^2^ weekly+Upa 200 mg/m^2^ once a day                     16.6                                                                                                  9.7                                                   5.6              40.7              0                          
  2013                                                                                  33     0/100                                                Gem 1,000 mg/m^2^ weekly+Upa 400 mg/m^2^ once a day                     16.1                                                                                                  12.5                                                  8.3              50.6              0                          
  Ueno et al. \[[@b33-crt-2017-105]\]                                                   2012   66                                                   0/100                                                                   Gem 1,000 mg/m^2^ weekly                                                                              na                                                    12.7             na                52                         0
                                                                                        68     0/100                                                TS1 80-120 mg/m^2^ D1-28 every 6 wk                                     na                                                                                                    13.8                                                  na               58                0                          
                                                                                        68     0/100                                                Gem 1,000 mg/m^2^ D1, 15+TS1 60-100 mg/m^2^ D1-14 every 3 wk            na                                                                                                    15.9                                                  na               62                0                          
  Stein et al. \[[@b34-crt-2017-105]\]                                                  2015   31                                                   100/?                                                                   mFOLFIRINOX                                                                                           na                                                    26.6             17.8              86                         41.9
  Hammel et al. \[[@b35-crt-2017-105]\]                                                 2016   136^[b)](#tfn2-crt-2017-105){ref-type="table-fn"}^   0/100                                                                   Gem 1,000 mg/m^2^ weekly±erlo100 mg/m^2^ once a day                                                   24                                                    16.5             8.4               69                         4

BR, borderline resectable; UR, unresectable; Tx, treatment; OS, overall survival; PFS, progression-free survival; 5FU, 5-fluorouracil; CCNU, lomustine; na, not available; MMC, mitomycin C; LV, leucovorin; Dip, dipyridamole; FOLFIRINOX, fluorouracil, lecovorin, irinotecan, oxaliplatin; Gem, gemcitabine; Doc, docetaxel; Oxalip, oxaliplatin; Cape, capecitabine; TS1, tegafur/gimeracil/oteracil; Upa, upamostat; mFOLFIRINOX, modified fluorouracil, leucovorin, irinotecan, oxaliplatin; erlo, erlotinib.

References in S4 Table,

Number of patient selected after 4-month chemotherapy.

###### 

Baseline characteristics of 25 cohort groups of induction chemotherapy plus chemoradiation for meta-analysis

  Author                                                                                  Year   Patients   BR/UR (%)   ICT (regimen/mo)   CCRT (CT/RT Gy)                                         Maintenance CT                                       Median OS (mo)   Median PFS (mo)   1-Year SR (%)   Resection rate (%)
  --------------------------------------------------------------------------------------- ------ ---------- ----------- ------------------ ------------------------------------------------------- ---------------------------------------------------- ---------------- ----------------- --------------- --------------------
  Wagener et al. \[[@b36-crt-2017-105]\]^[a)](#tfn3-crt-2017-105){ref-type="table-fn"}^   1989   19         0/100       5FUAdCDDP (6)      5FU/40                                                  Nil                                                  14               na                52              na
  Wagener et al. \[[@b37-crt-2017-105]\]                                                  1996   53         0/100       EpCDDP (2)         5FU/40                                                  EpCDDP                                               10.6             8.9               49              na
  Epelbaum et al. \[[@b38-crt-2017-105]\]                                                 2002   20         0/100       Gem (2)            Gem/50.4                                                Gem                                                  8                na                30              15
  Al-Sukhun et al. \[[@b39-crt-2017-105]\]                                                2003   20         0/100       PACE (2)           5FU/47.6                                                Nil                                                  13.4             na                52              15
  Mishra et al. \[[@b40-crt-2017-105]\]                                                   2005   20         0/100       IrinoGem (1.5)     Gem/50.4                                                Nil                                                  8.8              5.1               20              na
  Kurt et al. \[[@b41-crt-2017-105]\]                                                     2006   24         0/100       5FUGem (2)         Gem/50.4-54                                             5FUGem                                               11               6                 35              na
  Ko et al. \[[@b42-crt-2017-105]\]                                                       2007   25         0/100       GemCDDP (6)        Cape/50.4                                               Nil                                                  13.5             10.5              62              na
  Goldstein et al. \[[@b43-crt-2017-105]\]                                                2007   41         0/100       Gem (1)            5FU/54                                                  Gem (3)                                              11.7             7.1               46.3            na
  Moureau- Zabotto et al. \[[@b44-crt-2017-105]\]                                         2008   59         0/100       GemOx (2)          5FUOx/55                                                Nil                                                  12.2             7.6               52.1            na
  Marti et al. \[[@b45-crt-2017-105]\]                                                    2008   27         ?/?         GemCDDP (2)        GemCDDP/50.4                                            GemCDDP                                              13               7                 48              15.4
  Landry et al. \[[@b46-crt-2017-105]\]                                                   2010   11         100/0       GemCDDP5FU (1.5)   5FU/50.4                                                Gem                                                  13.4             na                61              20
  Nakachi et al. \[[@b47-crt-2017-105]\]                                                  2010   20         0/100       GemTS1 (3)         Gem/30^[b)](#tfn4-crt-2017-105){ref-type="table-fn"}^   Gem                                                  14.4             8.1               54.2            na
  Ch'ang et al. \[[@b48-crt-2017-105]\]                                                   2011   50         0/100       GOFL (3)           Gem/50.4                                                GOFL                                                 14.5             9.3               68              8
  Crane et al. \[[@b49-crt-2017-105]\]                                                    2011   69         ?/?         cetGemOx (2)       cetCap/50.4                                             60%^[c)](#tfn5-crt-2017-105){ref-type="table-fn"}^   19.2             12.5              66              13
  Milandri et al. \[[@b50-crt-2017-105]\]                                                 2011   33         0/100       GemOx (2)          Nil/25^[b)](#tfn4-crt-2017-105){ref-type="table-fn"}^   GemOx                                                14               11                63              18
  Goldstein et al. \[[@b51-crt-2017-105]\]                                                2012   48         0/100       GemOx (1)          5FU/54                                                  GemOx                                                15.5             11                70.2            na
  Kim et al. \[[@b52-crt-2017-105]\]                                                      2012   37         0/100       GemCDDP (2)        Cape/54                                                 Gem                                                  16.8             7.2               69.1            na
  Leone et al. \[[@b53-crt-2017-105]\]                                                    2013   39         38/62       GemOx (1)          Gem/50.4                                                Nil                                                  16.7             10.2              65              28
  Mukherjee et al. \[[@b54-crt-2017-105]\]                                                2013   38         0/100       GemCape (4)        Gem/50.4                                                Nil                                                  13.4             10.4              64.2            7.9
  Mukherjee et al. \[[@b54-crt-2017-105]\]                                                2013   36         0/100       GemCape (4)        Cape/50.4                                               Nil                                                  15.2             12                79.2            13.9
  Youl et al. \[[@b55-crt-2017-105]\]                                                     2014   78         0/100       Gem (2)            Gem/52.5                                                Nil                                                  12.7             8.7               53.6            na
  Esnaola et al. \[[@b56-crt-2017-105]\]                                                  2014   37         ?/?         cetGemOx (1.5)     Cap/54                                                  Nil                                                  11.8             10.4              48              32.4
  Ke et al. \[[@b57-crt-2017-105]\]                                                       2014   32         0/100       GemTS1 (1.5)       TS1/50.4                                                TS1                                                  15.2             9.3               75              na
  Herman et al. \[[@b58-crt-2017-105]\]                                                   2015   49         0/100       Gem (1)            Nil/33^[b)](#tfn4-crt-2017-105){ref-type="table-fn"}^   Gem                                                  13.9             7.8               59              8
  Hammel et al. \[[@b35-crt-2017-105]\]                                                   2016   133        0/100       Gem±erlo (4)       Cape/54                                                 Erlo                                                 15.2             9.9               65              4

BR, borderline resectable; UR, unresectable; ICT, induction chemotherapy; CCRT, concurrent chemoradiation; CT, chemotherapy; RT, radiotherapy; OS, overall survival; PFS, progression-free survival; SR, survival rate; 5FU, 5-fluorouracil; Ad, adriamycin; CDDP, cisplatin; nil, no; na, not available; Ep, epirubicin; Gem, gemcitabine; PACE, cisplatin, ctyarabine, caffeine, 5FU; Irino, irinotecan; Gem, gemcitabine; Ox, oxaliplatin; GOFL, gemcitabine, oxaliplatin, 5FU, leucovorin; cet, cetuximab; Cap, capecitabine; TS1, tegafur/gimeracil/oteracil; erlo, erlotinib.

References in S4 Table,

Stereotactic body radiotherapy,

60% patients received maintenance chemotherapy.

###### 

Comparison of 1-year survival between ICT+CCRT vs. CT

  Treatment                                                                   No. of studies   Meta-1-year survival (95% CI)                                                                                   I^2^
  --------------------------------------------------------------------------- ---------------- --------------------------------------------------------------------------------------------------------------- ------
  **All**                                                                     45               0.55 (0.51-0.59)                                                                                                70.6
  **CT**                                                                      20               0.52 (0.45-0.60)                                                                                                78.3
  **ICT+CCRT**                                                                25               0.58 (0.53-0.62)                                                                                                59.7
  **Randomization**                                                                                                                                                                                            
   No                                                                                                                                                                                                          
    CT                                                                        6                0.65 (0.53-0.76)                                                                                                73.9
    ICT+CCRT                                                                  21               0.55 (0.50-0.61)                                                                                                59.7
   Yes                                                                                                                                                                                                         
    CT                                                                        13               0.47 (0.38-0.56)                                                                                                78.1
    ICT+CCRT^[\*](#tfn6-crt-2017-105){ref-type="table-fn"}^                   4                0.67 (0.60-0.73)^[\*](#tfn6-crt-2017-105){ref-type="table-fn"},[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^   0
  **Resectability status**                                                                                                                                                                                     
   Unresectable only                                                                                                                                                                                           
    CT                                                                        16               0.50 (0.42- 0.58)                                                                                               76.1
    ICT+CCRT                                                                  20               0.57 (0.51- 0.63)                                                                                               64.8
   Borderline and unresectable                                                                                                                                                                                 
    CT                                                                        4                0.62 (0.40-0.82)                                                                                                85.4
    ICT+CCRT                                                                  5                0.59 (0.52-0.66)^[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^                                                 28.4
  **No. of chemotherapy agents**                                                                                                                                                                               
   One                                                                                                                                                                                                         
    CT                                                                        11               0.48 (0.40-0.57)                                                                                                77.2
    ICT+CCRT                                                                  6                0.56 (0.47-0.65)                                                                                                64.4
   Two or more                                                                                                                                                                                                 
    CT                                                                        9                0.58 (0.45-0.70)                                                                                                80.0
    ICT+CCRT                                                                  19               0.58 (0.52-0.64)                                                                                                60.5
   ICT duration                                                                                                                                                                                                
    CT                                                                        20               0.52 (0.45-0.60)                                                                                                78.3
    ICT+CCRT with ICT \< 3 mo                                                 18               0.55 (0.48-0.61)                                                                                                63.2
    ICT+CCRT with ICT ≥ 3 mo^[\*](#tfn6-crt-2017-105){ref-type="table-fn"}^   7                0.65 (0.60-0.70)^[\*](#tfn6-crt-2017-105){ref-type="table-fn"},[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^   0
   Maintenance CT                                                                                                                                                                                              
    CT                                                                        20               0.52 (0.45-0.60)                                                                                                78.3
    ICT+CCRT without maintenance CT                                           10               0.56 (0.47-0.64)                                                                                                62.1
    ICT+CCRT with maintenance CT                                              15               0.59 (0.52-0.65)                                                                                                59.0
   RT dosage                                                                                                                                                                                                   
    CT                                                                        20               0.52 (0.45-0.60)                                                                                                78.3
    ICT+CCRT with RT dosage \< 50 Gy                                          5                0.56 (0.48-0.63)^[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^                                                 0
    ICT+CCRT with RT dosage ≥ 50 Gy                                           20               0.58 (0.52-0.64)                                                                                                66.5
   Radiosensitizer                                                                                                                                                                                             
    CT                                                                        20               0.52 (0.45-0.60)                                                                                                78.3
    ICT+CCRT with gemcitabine                                                 8                0.50 (0.38-0.61)                                                                                                73.7
    ICT+CCRT with fluorouracil                                                12               0.64 (0.60-0.68)^[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^                                                 40.7
    ICT+CCRT with other                                                       3                0.56 (0.48-0.65)^[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^                                                 1.3
  **Study year**                                                                                                                                                                                               
   Before 2010                                                                                                                                                                                                 
    CT                                                                        5                0.45 (0.28-0.62)                                                                                                84.0
    ICT+CCRT                                                                  10               0.46 (0.40-0.51)^[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^                                                 40.6
   2010 or after 2010                                                                                                                                                                                          
    CT                                                                        15               0.55 (0.47-0.62)                                                                                                74.3
    ICT+CCRT                                                                  15               0.64 (0.60-0.68)^[a)](#tfn7-crt-2017-105){ref-type="table-fn"}^                                                 9.9

ICT, induction chemotherapy; CCRT, chemoradiation; CT, chemotherapy; CI, confidence interval; RT, radiotherapy.

p \< 0.05.

Based-on fixed-effects models
